Evidence map›Paper›PMID 38156359›Full record

ArticleAnnals of clinical and translational neurology2024

Effects of tirofiban on large vessel occlusion stroke are modified by etiology and renal function.

Chang Liu, Fengli Li, Liyuan Chen, Jiacheng Huang, Hongfei Sang, Thanh N Nguyen, Jeffrey L Saver, Mohamad Abdalkader, Weiling Kong, Jie Yang and 8 more

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Chang LiuDepartment of Neurology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Fengli LiDepartment of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.ORCID 0000-0002-5899-9270
Liyuan ChenDepartment of Neurology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Jiacheng HuangDepartment of Neurology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.ORCID 0000-0002-6962-7253
Hongfei SangNeurology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Thanh N NguyenDepartment of Neurology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.
Jeffrey L SaverNeurology, University of California in Los Angeles, Los Angeles, California, USA.
Mohamad AbdalkaderDepartment of Radiology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.
Weiling KongDepartment of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Jie YangDepartment of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Changwei GuoDepartment of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Chen GongDepartment of Neurology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Liping HuangDepartment of Neurology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Yanzhu PanDepartment of Neurology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Xinxin WangDepartment of Neurology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Yangmei ChenDepartment of Neurology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Zhongming QiuDepartment of Neurology, The 903rd Hospital of The Chinese People's Liberation Army, Hangzhou, China.ORCID 0000-0002-1622-9526
Wenjie ZiDepartment of Neurology, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.ORCID 0000-0001-6323-2659
Dalian Medical University · CNArmy Medical University · CNBoston University · US117th Hospital of People's Liberation Army · CNHangzhou First People's Hospital · CNUniversity of California, Los Angeles · US

Funding

Chongqing Technology Innovation and Application Development Project 2022TIAD-KPX0017National Natural Science Foundation of China 82001264National Natural Science Foundation of China 82071323The First Batch of Key Disciplines on Public Health in Chongqing
6 · The paper itself

Abstract

objectiveRenal function can modify the outcomes of large vessel occlusion (LVO) stroke across stroke etiologies in disparate degrees. The presence of renal function deficit can also impair the pharmacokinetics of tirofiban. Hence, this study aimed to investigate the roles of renal function in determining efficacy and safety of intravenous tirofiban before endovascular treatment (EVT) for acute ischemic stroke patients with large vessel occlusion (LVO).

methodsThis study was a post hoc exploratory analysis of the RESCUE-BT trial. The primary outcome was the proportion of patients achieving functional independence (modified Rankin scale 0-2) at 90 days, and the primary safety outcome was the rate of symptomatic intracranial hemorrhage (sICH).

resultsAmong 908 individuals with available serum creatinine, decreased estimated glomerular filtration rate (eGFR) status was noted more commonly in patients with cardioembolic stroke (CE), while large artery atherosclerosis (LAA) was predominant in patients with normal renal function. In LAA with normal renal function, tirofiban was associated with higher rates of functional independence at 90 days (41.67% vs 59.80%, p = 0.003). However, for LVO patients with renal dysfunction, tirofiban did not improve functional outcomes for any of the etiologies (LAA, p = 0.876; CE, p = 0.662; others, p = 0.894) and significantly increased the risk of sICH among non-LAA patients (p = 0.020). Mediation analysis showed tirofiban reduced thrombectomy passes (12.27%) and drug/placebo to recanalization time (14.25%) mediated its effects on functional independence.

conclusionThis present study demonstrated the importance of evaluating renal function before administering intravenous tirofiban among patients with LVO who are planned to undergo EVT.

Indexed as

Brain IschemiaIschemic StrokeStrokeHumansIntracranial HemorrhagesKidneyTirofibanTreatment OutcomeTirofiban

Identifiers

PMID38156359
PMCPMC10963294
OpenAlexW4390406580

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.